Investing in novel therapies demands courage, capital, and conviction. Early‑stage clinical trials remain one of the most challenging hurdles for biotech innovators, with traditional funders hesitant to support high‑risk Phase I and Phase II assets.
MCI’s Clinical Trial Funding Insurance provides a market‑leading solution: a dedicated indemnity product that helps biotechs unlock capital, reduce financial exposure, and retain greater control of their drug development program.
Our underwriting approach combines traditional expertise with proprietary modelling and deep clinical insight – helping innovators progress to trial with confidence.
What We Offer
WHAT IS COVERED
- Insurance covering incurred clinical trial costs when a trial fails to meet negotiated Trial Parameters aligned to primary protocol endpoints.
- Costs indemnified may include (but are not limited to):
- CRO fees
- Clinical protocol design and associated consultancy
- Hospital, investigator, and medical practitioner costs
- Monitoring, data collection, and analysis
PROGRAMME STRUCTURES
- Dedicated, stand‑alone CTF insurance
- Ground‑up indemnity for covered trial failures
- Coverage validated as acceptable collateral by select lenders and financiers*
- One policy per clinical trial
*MCI can refer insureds to regulated financial advisors but cannot advise on or negotiate financing instruments
Trial/Asset Appetite
- Coverage considered for:
- Phase 1, Phase 2 and select small Phase 3 trials
- Trial budgets typically USD/EUR/GBP 3M – 35M
- Trial durations – 24 months planned, extendable up to 48 months
- Sponsors conducting trials with:
- Small molecule, peptide, antibody, and some biologic assets
- CRO partners already engaged
- Completed or regulator-approved clinical trial protocols
- Not currently insurable:
- Gene therapies
- Opioids and drugs with high likeability scores
- Assets with budgets exceeding USD/EUR/GBP 45M
TERRITORIAL CAPACITY
- Biotech companies domiciled in:
- USA
- UK
- Europe
- Canada
*However, trial sites can be located worldwide
Why we’re different
- The only dedicated, specialist Clinical Trial Funding Insurance team globally
- Combines traditional underwriting, proprietary modelling, and clinical expertise
- Supports funding accessibility, potentially enabling:
-
- Retention of equity for biotech founders
- Broader investor participation, including those with lower risk appetite
Clinical Trial Funding Insurance team
